Comparison of Malignancy and Spatial Distribution between Latent and Clinical Prostate Cancer--an eight-year biopsy study

Abstract

BackgroundCurrent prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) is consistent, and to verify the current clinically significant prostate cancer criteria.Methods:Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. ResultsIn lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP ≥ 2, 12.5% had tumor volume ≥ 0.5 ml, and 16.7 % had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP ≥ 2, and 82.5% had tumor volume of ≥ 0.5ml. 56.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. ConclusionThe malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa are consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.